ImmunoScape
ImmunoScape55ImmunoScape
Developing novel immunotherapies and diagnostics for cancer.
About
What does ImmunoScape do?
ImmunoScape is a biotechnology company focused on developing novel immunotherapies and diagnostics for cancer. They leverage their proprietary platform to identify and target key immune pathways involved in cancer progression and treatment response. The company is actively pursuing clinical trials to validate their therapeutic candidates.
What is ImmunoScape's revenue?
StartupHub estimates ImmunoScape's annual revenue at $65.9M (range $36.1M to $170.5M, 44% confidence), based on comparable companies in the sector.
What is ImmunoScape's valuation?
StartupHub estimates ImmunoScape's effective valuation at $935.6M (range $654.9M to $1.2B, 38% confidence), based on comparable companies in the sector.
How much funding has ImmunoScape raised?
ImmunoScape has raised a total of $50M in funding. The most recent round on record is Series B2.
Where is ImmunoScape headquartered?
ImmunoScape is headquartered in Singapore, Singapore.
When was ImmunoScape founded?
ImmunoScape was founded in 2017.
What industry does ImmunoScape operate in?
ImmunoScape operates in Biotechnology, Cancer, Immunotherapy, Diagnostics, Biotech, Drug Discovery.
“Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments.”
View on Reddit“Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments.”
View on Reddit“Cue Biopharma announced a strategic collaboration with ImmunoScape that includes $15 million in upfront payments, a figure representing 30% of the company's market capitalization.”
View on Reddit“Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors.”
View on Reddit“Cue Biopharma has secured a major strategic collaboration providing a cash infusion equivalent to 25% of its market capitalization, plus a substantial 40% equity stake in its partner, ImmunoScape.”
View on Reddit“ImmunoScape's Machine Learning Breakthrough: Revolutionizing T-Cell Immunotherapies.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.